Latest Evion (ASX:EVG) News

Small-cap resources led the week’s biggest moves, but sharp falls in Bounty Oil and Nyrada showed how quickly investors can sell when funding and deal terms remain uncertain.
Gold, copper, rare earths and takeover activity supplied the strongest gains, while several companies still need more cash before they can deliver their plans.

Evion Group has moved its flagship Maniry graphite project into the development stage and secured a binding German offtake terms sheet, but its FY2026 accounts carry a material going concern warning. The company also faces an unpaid A$730,000 placement shortfall as it funds graphite, fluorspar and downstream expansion plans.

Evion has identified a previously unmined 200m by 200m prospect at its Carp Fluorspar Project in Nevada, just 300m from the historic South Pit. Assays are pending, with geophysical surveys and a potential maiden drilling programme next in line.

Evion Group will pay a mandatory 3% initial CAPEX levy to Madagascar's government as part of mining permit approvals for its Maniry Graphite Project, aligning with the country’s 2023 Mining Law.

Evion Group launches a systematic exploration campaign at its Carp Fluorspar Project in Nevada, targeting critical mineral supply amid US import reliance.

Exploration wins and funding deals kept the materials sector busy, but price action was uneven. Big winners came from fresh drill results and new targets, while several stocks gave back early gains after trading resumed.

Evion Group’s Panthera Graphite Technologies joint venture posted a US$530,000 EBITDA in its first full year of commercial production, operating at just 20-25% capacity and setting the stage for substantial earnings growth.

Evion Group has appointed former Australian Ambassador to the US, Arthur Sinodinos, as Strategic Advisor to accelerate its US critical minerals strategy following its acquisition of the CARP Fluorspar Project in Nevada.

Small-cap materials stocks swung hard as fresh funding, mine build decisions and standout drill hits drove the week’s biggest moves. Gold, lithium, rare earths and tungsten names all drew buying, while a few raisings and weak follow-through after trading halts kept losses sharp.

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.

Evion Group has increased the size of its second tranche placement, lifting total capital raised to A$7.24 million through the issue of over 241 million shares at 3 cents each. The second tranche awaits shareholder approval at a July meeting, including director participation and free attaching options.

Evion Group confirms high-grade fluorspar assays up to 88.15% CaF2 at its Carp Project in Nevada, validating a large, near-surface mineralised system. The company plans an extensive exploration program to capitalise on the US critical minerals demand.